|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 199.80 HKD | +7.25% |
|
+17.53% | +46.91% |
| 08-04 | Fujian Haixi Pharma Receives FDA Clearance for Eye Disease Drug Trial | MT |
| 07-15 | Fujian Haixi Pharmaceuticals Co., Ltd. Announces Resignation of Wang Xinkun as A Non-Executive Director | CI |
| Market Cap | 12.62B 14.66B 1.87B 1.62B 1.51B 1.39B 2.63B 178B 2.66B 17.84B 6.98B 88.9B 7.02B 6.87B 295B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 12.62B 14.66B 1.87B 1.62B 1.51B 1.39B 2.63B 178B 2.66B 17.84B 6.98B 88.9B 7.02B 6.87B 295B | EV / Sales 2026 * |
17.5x | EV / Sales 2027 * | 14.8x |
| Free-Float |
18.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +7.25% | ||
| 1 week | +17.53% | ||
| Current month | +16.84% | ||
| 1 month | -3.57% | ||
| 3 months | -18.18% | ||
| 6 months | +50.57% | ||
| Current year | +46.91% |
| 1 week | 163 |  | 213.4 |
| 1 month | 163 | | 222.8 |
| Current year | 125.3 | | 302.4 |
| 1 year | 97.5 | | 302.4 |
| 3 years | 97.5 | | 302.4 |
| 5 years | 97.5 | | 302.4 |
| 10 years | 97.5 | | 302.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yan Feng
PRN | Corporate Officer/Principal | 51 | 2012-03-26 |
Xin Shan Kang
CEO | Chief Executive Officer | 55 | 2012-03-26 |
Jun Huan Zhang
DFI | Director of Finance/CFO | 56 | 2021-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Xin Shan Kang
CHM | Chairman | 55 | 2017-10-31 |
Yan Feng
BRD | Director/Board Member | 51 | 2017-10-31 |
Guang Ming Chen
BRD | Director/Board Member | 62 | 2023-09-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.25% | +17.53% | - | - | 1.87B | |
| -0.51% | -8.60% | +45.08% | +148.21% | 995B | |
| +0.20% | -4.42% | +49.05% | +50.81% | 614B | |
| -0.53% | -7.37% | +23.64% | +65.03% | 431B | |
| +1.31% | +0.11% | +41.78% | +36.72% | 353B | |
| +0.79% | -3.14% | +31.62% | +39.86% | 293B | |
| +4.34% | -10.93% | +4.26% | +7.46% | 245B | |
| -5.84% | -14.30% | -5.30% | -46.91% | 210B | |
| +2.94% | -0.78% | +29.17% | +60.32% | 210B | |
| +3.13% | +0.69% | +18.11% | +71.90% | 168B | |
| Average | +1.43% | -3.62% | +26.38% | +48.15% | 352.01B | |
| Weighted average by Cap. | +1.78% | -5.88% | +33.62% | +70.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 722M 839M 107M 92.87M 86.59M 79.54M 150M 10.17B 152M 1.02B 399M 5.09B 402M 393M 16.85B | 850M 988M 126M 109M 102M 93.64M 177M 11.98B 179M 1.2B 470M 5.99B 473M 462M 19.84B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-05 | HK$199.80 | +7.25% | 334,450 |
| 26-08-04 | HK$186.30 | +5.08% | 177,600 |
| 26-08-03 | HK$177.30 | +3.68% | 140,700 |
| 26-07-31 | HK$171.00 | +4.72% | 133,200 |
| 26-07-30 | HK$163.30 | -3.94% | 218,300 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
160.35CNY
Average target price
251.05CNY
Spread / Average Target
+56.56%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2637 Stock
Select your edition
All financial news and data tailored to specific country editions
